Publication Name	World Journal of Biological Chemistry
Manuscript ID	73021
Country	Greece

Received	2021-11-06 15:46
Peer-Review Started	2021-11-06 15:47
To Make the First Decision
Return for Revision	2021-12-27 08:11
Revised	2021-12-28 16:24
Second Decision	2022-02-28 05:42
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2022-03-06 23:56
Articles in Press	2022-03-06 23:56
Publication Fee Transferred
Edit the Manuscript by Language Editor	2022-02-03 09:49
Typeset the Manuscript	2022-03-21 15:39
Publish the Manuscript Online	2022-03-23 09:06

ISSN	1949-8454 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Cell Biology
Manuscript Type	Basic Study
Article Title	Mesenchymal stromal cell delivery as a potential therapeutic strategy against COVID-19: Promising evidence from in vitro results
Manuscript Source	Invited Manuscript
All Author List	Panagiotis Mallis, Theofanis Chatzistamatiou, Zetta Dimou, Eirini-Faidra Sarri, Eleni Georgiou, Maria Salagianni, Vasiliki Triantafyllia, Evangelos Andreakos, Catherine Stavropoulos-Giokas and Efstathios Michalopoulos
ORCID	Author(s) ORCID Number Panagiotis Mallis http://orcid.org/0000-0001-9429-190X Theofanis Chatzistamatiou http://orcid.org/0000-0003-4895-0155 Zetta Dimou http://orcid.org/0000-0003-2721-0780 Eirini-Faidra Sarri http://orcid.org/0000-0002-5185-0879 Eleni Georgiou http://orcid.org/0000-0001-6446-2069 Maria Salagianni http://orcid.org/0000-0001-9821-1559 Vasiliki Triantafyllia http://orcid.org/0000-0001-5832-4014 Evangelos Andreakos http://orcid.org/0000-0001-5536-1661 Catherine Stavropoulos-Giokas http://orcid.org/0000-0003-0698-6061 Efstathios Michalopoulos http://orcid.org/0000-0002-1901-6294
Funding Agency and Grant Number
Corresponding Author	Panagiotis Mallis, MSc, PhD, Associate Research Scientist, Teaching Assistant, Hellenic Cord Blood Bank, Biomedical Research Foundation Academy of Athens, 4 Soranou Ephessiou Street, Athens 11527, Athens, Greece. pmallis@bioacademy.gr
Key Words	SARS-CoV-2; COVID-19; MSCs; Stem cell therapy; Cytokine storm; Immunomodulation
Core Tip	Coronavirus disease 2019 (COVID-19) is responsible for the acute respiratory distress syndrome occurrence, a disorder that might prove life-threatening for a great number of hospitalized patients. As an alternative to the already evaluated therapeutic protocols, mesenchymal stromal cells (MSCs) can be evaluated as a potential stem cell therapy. MSCs exert key immunoregulatory properties, either through direct or indirect contact. In the current study, stimulated Wharton’s Jelly and bone marrow-MSCs produced high levels of anti-inflammatory cytokines and growth factors and also efficiently performed the M2 phenotype switch of macrophages. Considering this data, MSCs could be considered as a valuable stem cell therapy for better COVID-19 management.
Publish Date	2022-03-23 09:06
Citation	Mallis P, Chatzistamatiou T, Dimou Z, Sarri EF, Georgiou E, Salagianni M, Triantafyllia V, Andreakos E, Stavropoulos-Giokas C, Michalopoulos E. Mesenchymal stromal cell delivery as a potential therapeutic strategy against COVID-19: Promising evidence from in vitro results. World J Biol Chem 2022; 13(2): 47-65
URL	https://www.wjgnet.com/1949-8454/full/v13/i2/47.htm
DOI	https://dx.doi.org/10.4331/wjbc.v13.i2.47

Full Article (PDF)	WJBC-13-47.pdf
Full Article (Word)	WJBC-13-47.docx
The ARRIVE Guidelines	73021-The-ARRIVE-Guidelines-revision.pdf
Manuscript File	73021_Auto_Edited-YXX-Wang TQ.docx
Answering Reviewers	73021-Answering reviewers.pdf
Audio Core Tip	73021-Audio core tip.aac
Biostatistics Review Certificate	73021-Biostatistics statement.pdf
Conflict-of-Interest Disclosure Form	73021-Conflict-of-interest statement.pdf
Copyright License Agreement	73021-Copyright license agreement.pdf
Institutional Animal Care and Use Committee Approval Form or Document	73021-Institutional animal care and use committee statement.pdf
Institutional Review Board Approval Form or Document	73021-Institutional review board statement.pdf
Non-Native Speakers of English Editing Certificate	73021-Language certificate.pdf
Supplementary Material	73021-Supplementary material.pdf
Peer-review Report	73021-Peer-review(s).pdf
Scientific Misconduct Check	73021-Bing Xing YX-2.png
Scientific Editor Work List	73021-Scientific editor work list.pdf
CrossCheck Report	73021-CrossCheck report.pdf